- Company
- AI Solution
- R&D
- Business
- Newsroom
ENG
- Company
- AI Solution
- R&D
- Business
- Newsroom
ENG
SM-ARS®
SM-ARS®
Small Molecule-Automatic Report System
Small Molecule-
Automatic Report System
SM-ARS® is an AI-driven platform designed for the rapid discovery and optimization of small molecule drug candidates through advanced molecular structural design.
SM-ARS® is an AI-driven platform designed for the rapid discovery and optimization of small molecule drug candidates through advanced molecular structural design.
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Efficient Exploration with SM-ARS®
to Minimize Iterative Experiments
Traditional drug development is a costly and time-consuming process involving repetitive experiments on millions of compounds. Bottlenecks often occur at every stage, from Hit Discovery to Lead Optimization, particularly for novel targets where low predictability makes them high-risk. SM-ARS® eliminates these bottlenecks by delivering fast, high-precision candidate generation to maximize research efficiency.
Overcoming the High Barriers of
Drug Discovery with SM-ARS®
Overcoming the High Barriers of
Drug Discovery
with SM-ARS®
Powered by Supercomputing Excellence
— Precision Design of Viable Candidates from 10 Billion Compounds
AI and Supercomputing
— Precision Design of Viable Candidates
from 10 Billion Compounds
Using AI-driven virtual screening and structural analysis, it identifies promising candidates while eliminating high-risk structures early, enabling researchers to advance with fewer experiments. Our precision design process is supported by the ABSC high-performance computing environment. This robust infrastructure ensures that even as the scale of exploration expands, your research workflow remains stable, efficient, and uninterrupted.
At its core is Syntekabio’s proprietary DeepMatcher® technology—an AI model combining virtual screening with 3D structure-based binding prediction to evaluate binding potential and stability at the molecular level.
Core Process of SM-ARS®
Core Process of
SM-ARS®
Core Process of
SM-ARS®
01
Target Analysis
AI-driven prediction of structures, binding sites and binding pose from structural data.
For de novo targets, we engineer novel molecules from scratch based on publicly available protein structures and peer-reviewed literature. By integrating these foundational insights, we perform precise de novo design and advanced simulations to accurately predict binding affinity and interaction stability.
01
Target Analysis
AI-driven prediction of structures, binding sites and binding pose from structural data.
For de novo targets, we engineer novel molecules from scratch based on publicly available protein structures and peer-reviewed literature. By integrating these foundational insights, we perform precise de novo design and advanced simulations to accurately predict binding affinity and interaction stability.
01
Target Analysis
AI-driven prediction of structures, binding sites and binding pose from structural data.
For de novo targets, we engineer novel molecules from scratch based on publicly available protein structures and peer-reviewed literature. By integrating these foundational insights, we perform precise de novo design and advanced simulations to accurately predict binding affinity and interaction stability.
02
Virtual Screening
Rapidly evaluate 10 billion+ compounds using DeepMatcher® to identify chemically feasible leads.
The LM-VS™ evaluates binding potential at scale, utilizing sepcific scoring algorithms to filter for candidates with the high probability of synthetic success.
LM-VS™
02
Virtual Screening
Rapidly evaluate 10 billion+ compounds using DeepMatcher® to identify chemically feasible leads.
The LM-VS™ evaluates binding potential at scale, utilizing sepcific scoring algorithms to filter for candidates with the high probability of synthetic success.
LM-VS™
02
Virtual Screening
Rapidly evaluate 10 billion+ compounds using DeepMatcher® to identify chemically feasible leads.
The LM-VS™ evaluates binding potential at scale, utilizing sepcific scoring algorithms to filter for candidates with the high probability of synthetic success.
LM-VS™
03
Binding Prediction and Optimization
3D structural simulations and CNN-based modeling to maximize binding affinity, stability, and pose accuracy.
DeepMatcher utilize advanced 3D simulations and Convolutional Neural Networks (CNN) to predict binding affinity and molecular stability. Our flexible docking simulate real-world molecular dynamics to derive optimized binding poses and superior lead characteristics.
DEEPMATCHER®
03
Binding Prediction and Optimization
3D structural simulations and CNN-based modeling to maximize binding affinity, stability, and pose accuracy.
DeepMatcher utilize advanced 3D simulations and Convolutional Neural Networks (CNN) to predict binding affinity and molecular stability. Our flexible docking simulate real-world molecular dynamics to derive optimized binding poses and superior lead characteristics.
DEEPMATCHER®
03
Binding Prediction and Optimization
3D structural simulations and CNN-based modeling to maximize binding affinity, stability, and pose accuracy.
DeepMatcher utilize advanced 3D simulations and Convolutional Neural Networks (CNN) to predict binding affinity and molecular stability. Our flexible docking simulate real-world molecular dynamics to derive optimized binding poses and superior lead characteristics.
DEEPMATCHER®
04
Data Integration & Reporting
Delivering refined lead candidates in a prioritized report format
The report provide refined candidate lists supported by aggregated metrics, ensuring all results are formatted for immediate experimental validation and downstream pipeline progression.
04
Data Integration & Reporting
Delivering refined lead candidates in a prioritized report format
The report provide refined candidate lists supported by aggregated metrics, ensuring all results are formatted for immediate experimental validation and downstream pipeline progression.
04
Data Integration & Reporting
Delivering refined lead candidates in a prioritized report format
The report provide refined candidate lists supported by aggregated metrics, ensuring all results are formatted for immediate experimental validation and downstream pipeline progression.
Core Value of SM-ARS®
80%
Innovative Time Reduction
Reducing hit discovery timelines from months to within three weeks through AI-driven automation
80%
Innovative Time Reduction
Reducing hit discovery timelines from months to within three weeks through AI-driven automation
52%
R&D Cost Reduction
Minimizing unnecessary experiments and candidate exploration costs through in silico analysis in the preclinical stage
52%
R&D Cost Reduction
Minimizing unnecessary experiments and candidate exploration costs through in silico analysis in the preclinical stage
60%
Reduced Risk of Clinical Failure
Early validation of binding stability and target suitability through AI-based structural prediction and MD simulations
60%
Reduced Risk of Clinical Failure
Early validation of binding stability and target suitability through AI-based structural prediction and MD simulations
70%
Enhanced Target Flexibility
Expanding applicability and pipeline flexibility through AI predictive models suitable for rare and novel targets
70%
Enhanced Target Flexibility
Expanding applicability and pipeline flexibility through AI predictive models suitable for rare and novel targets
80%
Innovative Time Reduction
Reducing hit discovery timelines from months to within three weeks through AI-driven automation
80%
Innovative Time Reduction
Reducing hit discovery timelines from months to within three weeks through AI-driven automation
52%
R&D Cost Reduction
Minimizing unnecessary experiments and candidate exploration costs through in silico analysis in the preclinical stage
52%
R&D Cost Reduction
Minimizing unnecessary experiments and candidate exploration costs through in silico analysis in the preclinical stage
60%
Reduced Risk of Clinical Failure
Early validation of binding stability and target suitability through AI-based structural prediction and MD simulations
60%
Reduced Risk of Clinical Failure
Early validation of binding stability and target suitability through AI-based structural prediction and MD simulations
70%
Enhanced Target Flexibility
Expanding applicability and pipeline flexibility through AI predictive models suitable for rare and novel targets
70%
Enhanced Target Flexibility
Expanding applicability and pipeline flexibility through AI predictive models suitable for rare and novel targets
These figures are based on analysis data from internal Syntekabio projects and proof-of-concept (PoC) studies conducted between 2021 and 2025.
These figures are based on analysis data from internal Syntekabio projects and proof-of-concept (PoC) studies conducted between 2021 and 2025.
SM-ARS®
SM-ARS®
Key Applications
Key Applications
PoC Validation
AI-driven candidate discovery enables rapid PoC validation without extensive upfront investment in biopharmaceuticals.
PoC Validation
AI-driven candidate discovery enables rapid PoC validation without extensive upfront investment in biopharmaceuticals.
PoC Validation
AI-driven candidate discovery enables rapid PoC validation without extensive upfront investment in biopharmaceuticals.
Early-Stage Novel Target Development
Rapidly derive candidates even for targets with limited or no structural information through AI-driven de novo design.
Early-Stage Novel Target Development
Rapidly derive candidates even for targets with limited or no structural information through AI-driven de novo design.
Early-Stage Novel Target Development
Rapidly derive candidates even for targets with limited or no structural information through AI-driven de novo design.
Specific target Application
AI-driven exploration enables the discovery of diverse structural scaffolds with varying mechanisms of action to specific targets.
Specific target Application
AI-driven exploration enables the discovery of diverse structural scaffolds with varying mechanisms of action to specific targets.
Specific target Application
AI-driven exploration enables the discovery of diverse structural scaffolds with varying mechanisms of action to specific targets.
Pipeline Expansion
Rapidly discover new chemicals by screening targets or indications, accelerating pipeline expansion for new Indication development.
Pipeline Expansion
Rapidly discover new chemicals by screening targets or indications, accelerating pipeline expansion for new Indication development.
Pipeline Expansion
Rapidly discover new chemicals by screening targets or indications, accelerating pipeline expansion for new Indication development.
Business Models
Business Models
Pre-Discovery Package Model
AI Driven Asset Program
Delivery of Ready-to-Use Candidate Sets
Pre-selected pipeline compounds are delivered as packaged assets through large-scale AI analysis, enabling rapid evaluation and immediate research integration.
Candidate Targets: BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others.
Pre-validated compound packages
Reduced research time and costs
Ideal for short-term use and PoC (Proof of Concept) projects
Learn More About Asset List
Learn More About Asset List
Pre-Discovery Package Model
AI Driven Asset Program
Delivery of Ready-to-Use Candidate Sets
Pre-selected pipeline compounds are delivered as packaged assets through large-scale AI analysis, enabling rapid evaluation and immediate research integration.
Candidate Targets: BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others.
Pre-validated compound packages
Reduced research time and costs
Ideal for short-term use and PoC (Proof of Concept) projects
Learn More About Asset List
Learn More About Asset List
Pre-Discovery Package Model
AI Driven Asset Program
Delivery of Ready-to-Use Candidate Sets
Pre-selected pipeline compounds are delivered as packaged assets through large-scale AI analysis, enabling rapid evaluation and immediate research integration.
Candidate Targets: BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others.
Pre-validated compound packages
Reduced research time and costs
Ideal for short-term use and PoC (Proof of Concept) projects
Learn More About Asset List
Learn More About Asset List
Annual Subscription Model
PaaS
(Platform as a Service)
Dedicated AI Platform for Small-Molecule Drug Discovery
Exclusive, time-bound access to an AI-driven small-molecule discovery platform, integrating large-scale virtual screening, high-performance computing, and dedicated scientific support—operated as an extension of in-house R&D.
Unified subscription for platform, compute, and expertise
HPC with dedicated discovery scientists
Pre-defined annual hit discovery scope
Consult on PaaS Model
Consult on PaaS Model
Annual Subscription Model
PaaS
(Platform as a Service)
Dedicated AI Platform for Small-Molecule Drug Discovery
Exclusive, time-bound access to an AI-driven small-molecule discovery platform, integrating large-scale virtual screening, high-performance computing, and dedicated scientific support—operated as an extension of in-house R&D.
Unified subscription for platform, compute, and expertise
HPC with dedicated discovery scientists
Pre-defined annual hit discovery scope
Consult on PaaS Model
Consult on PaaS Model
Annual Subscription Model
PaaS
(Platform as a Service)
Dedicated AI Platform for Small-Molecule Drug Discovery
Exclusive, time-bound access to an AI-driven small-molecule discovery platform, integrating large-scale virtual screening, high-performance computing, and dedicated scientific support—operated as an extension of in-house R&D.
Unified subscription for platform, compute, and expertise
HPC with dedicated discovery scientists
Pre-defined annual hit discovery scope
Consult on PaaS Model
Consult on PaaS Model
Customized Discovery Model
FFS
(Fee For Service)
Optimized candidate discovery through predictive analysis.
This service provides customized drug candidate discovery based on customer targets, supported by AI-driven analysis and flexible milestone-based pricing.
Target-specific screening with compound requirements incorporated
Delivery of globally competitive analysis results
Foundation for mid- to long-term collaboration and joint research
Contact Us About Target
Contact Us About Target
Customized Discovery Model
FFS
(Fee For Service)
Optimized candidate discovery through predictive analysis.
This service provides customized drug candidate discovery based on customer targets, supported by AI-driven analysis and flexible milestone-based pricing.
Target-specific screening with compound requirements incorporated
Delivery of globally competitive analysis results
Foundation for mid- to long-term collaboration and joint research
Contact Us About Target
Contact Us About Target
Customized Discovery Model
FFS
(Fee For Service)
Optimized candidate discovery through predictive analysis.
This service provides customized drug candidate discovery based on customer targets, supported by AI-driven analysis and flexible milestone-based pricing.
Target-specific screening with compound requirements incorporated
Delivery of globally competitive analysis results
Foundation for mid- to long-term collaboration and joint research
Contact Us About Target
Contact Us About Target
Customized Discovery Model
FFS
(Fee For Service)
Optimized candidate discovery through predictive analysis.
This service provides customized drug candidate discovery based on customer targets, supported by AI-driven analysis and flexible milestone-based pricing.
Target-specific screening with compound requirements incorporated
Delivery of globally competitive analysis results
Foundation for mid- to long-term collaboration and joint research
Contact Us About Target
Contact Us About Target
Start Your Small-Molecule Drug Discovery
with SM-ARS®
Start Your Small-Molecule
Drug Discovery with SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Contact Us About SM-ARS®
Global Premier AI
Drug Partner
Innovate with us.
Contact Us
Contact Us
© Syntekabio Co., Ltd. All rights reserved.
General Inquiries
Investor Relations / Press
Business Development / Partnerships
Data Center
Family Sites
© Syntekabio Co., Ltd. All rights reserved.
Global Premier AI
Drug Partner
Innovate with us.
Contact Us
Contact Us
© Syntekabio Co., Ltd. All rights reserved.
General Inquiries
Investor Relations / Press
Business Development / Partnerships
Data Center
Family Sites